CareRx (TSE:CRRX) has released an update.
Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
CareRx Corporation has reported its financial results for Q2 2024, showing an increase in adjusted EBITDA to $7.5 million despite a slight revenue dip from the previous year. The Company also faced a net loss of $1.4 million, attributed to a one-off impairment charge related to the sale of a non-core pharmacy operation. CareRx continues to drive efficiencies and manage costs to strengthen its market position in the pharmacy services sector.
For further insights into TSE:CRRX stock, check out TipRanks’ Stock Analysis page.
